王业明,曹彬.抗流感病毒药物的回顾、现状和展望[J].Chinese journal of Epidemiology,2018,39(8):1051-1059 |
抗流感病毒药物的回顾、现状和展望 |
Perspectives of antiviral drugs used on influenza |
Received:May 31, 2018 |
DOI:10.3760/cma.j.issn.0254-6450.2018.08.008 |
KeyWord: 抗病毒药物 流感 治疗 神经氨酸酶抑制剂 |
English Key Word: Antiviral agent Influenza Therapy Neuraminidase inhibitors |
FundProject:国家杰出青年科学基金(81425001/H0104);科技部应急专项(10600100000015001206) |
Author Name | Affiliation | E-mail | Wang Yeming | Department of Pulmonary and Critical Care Medicine, China-Japan Friendship Hospital National Clinical Research Center for Respiratory Diseases, Department of Respiratory Medicine, Capital Medical University, Beijing 100029, China | | Cao Bin | Department of Pulmonary and Critical Care Medicine, China-Japan Friendship Hospital National Clinical Research Center for Respiratory Diseases, Department of Respiratory Medicine, Capital Medical University, Beijing 100029, China | caobin_ben@163.com |
|
Hits: 4713 |
Download times: 2264 |
Abstract: |
抗流感病毒治疗作为救治流感感染的关键手段,但目前临床可及的有效抗病毒药物仅有神经氨酸酶抑制剂(neuraminidase inhibitors,NAIs)。由于NAIs疗效的限制和耐药情况的出现,亟需研发疗效更优和耐药率更低的新型抗流感病毒药物。目前,诸多不同抗流感病毒机制的药物已处于上市前临床试验阶段。 |
English Abstract: |
Antiviral drugs on influenza are important in the control program of influenza. Options for influenza treatment are currently limited to using the neuraminidase inhibitors (NAIs). Given limited effectiveness of NAIs and related resistance, there remains an urgent need for the development of influenza antiviral drugs that can improve the efficacy and provide low propensity of viral resistance. Several influenza-related antiviral drugs that are currently under the late-stage clinical trials all appear differently in the mechanism of action. It is hoped that when new antiviral drugs are licensed, care and outcomes of severe influenza cases will be improved. |
View Fulltext
Html FullText
View/Add Comment Download reader |
Close |